Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema

May 19, 2019 updated by: Eye-yon Medical

Prospective, Randomized Crossover Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema

The Hyper-CL™ lenses are indicated for therapeutic use as a bandage to protect the corneal surface and to relieve corneal pain in the treatment of acute or chronic ocular pathologies, such as bullous keratopathy, corneal erosions, entropion, corneal edema, and corneal dystrophies as well as post-surgical conditions resulting from cataract extraction and corneal surgery. The lenses may be prescribed for daily wear with removal for cleaning and disinfection (chemical, not heat) prior to reinsertion, as recommended by the eye care professional.

In addition Hyper-CL™ contact lenses can also provide optical correction during healing if required.

Study Overview

Detailed Description

This study is a prospective, randomized crossover study. The primary aim of this study is to assess the safety and effectiveness of using the Hyper-CL™ lens +salt solution (5% NaCl) as compared with using regular contact lens + salt solution (5% NaCl) in subjects suffering from corneal edema. Safety will be assessed by evaluating the rate of adverse events and adverse device effects occurred throughout the study period. Effectiveness will be assessed by measuring changes in corneal thickness and visual acuity.

Subjects with corneal edema will be the study population. Only subjects who have signed the informed consent form and meet all the eligibility criteria listed below will be qualified for enrollment. The study will encompass a total of up to 80 subjects who will complete the Protocol follow-up schedule.

Each subject will be treated with:

Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments. Subject will be equally allocated to one of the following 2 crossover regimen based on a randomization scheme with blocks stratified by center: A-B; B-A

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Beer- Sheva, Israel
        • Soroka MC
      • Ramat Gan, Israel
        • Sheba MC
      • Katowice, Poland
        • Katowice MC
      • Lublin, Poland
        • Lublin MC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subject is over 18 years old
  2. Subject with corneal edema in the visual access
  3. Subject with visual acuity of 6/20 or worse (equivalent ETDRS) clinically explained by corneal edema
  4. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.

Exclusion Criteria:

  1. Subject with active Herpes keratitis
  2. Subject with scarred cornea
  3. Subject who is suffering from erosions and/or infections of the cornea (red eye)
  4. Subject with glaucoma shunts (e.g. Ahmed valve) and or bleb
  5. Subject who require chronic administration of any topical ophthalmic beside lubrication eye drops and steroids or anti glaucoma drags
  6. Subject who is currently participating or have participated in an investigational study, other than this study, within the past 60 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment A-B
Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
Experimental: Treatment B-A
Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
frequency and severity of all treatment-related adverse events
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
Up to 28 days (or 21 days if wash out is not needed).
Percent of subjects with corneal thickness decrease of at least 8% and or visual acuity improvement of at least 1 line following treatment with the Hyper-CL™ lens + salt solution
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
assess by physiological parameter
Up to 28 days (or 21 days if wash out is not needed).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent of subjects with corneal thickness decrease of at least 8%.
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
assess by physiological parameter
Up to 28 days (or 21 days if wash out is not needed).
Percent of subjects with visual acuity improvement of at least 1 line
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
assess by physiological parameter
Up to 28 days (or 21 days if wash out is not needed).
Corneal thickness decrease
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
assess by physiological parameter
Up to 28 days (or 21 days if wash out is not needed).
change in Measurement Best Corrected Distance Visual Acuity (BCDVA)
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
Up to 28 days (or 21 days if wash out is not needed).
change in Subject comfort questionnaire
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
Up to 28 days (or 21 days if wash out is not needed).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2016

Primary Completion (Actual)

October 1, 2018

Study Completion (Actual)

November 28, 2018

Study Registration Dates

First Submitted

January 11, 2016

First Submitted That Met QC Criteria

January 17, 2016

First Posted (Estimate)

January 21, 2016

Study Record Updates

Last Update Posted (Actual)

May 21, 2019

Last Update Submitted That Met QC Criteria

May 19, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ECL00030

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on CORNEAL EDEMA

Clinical Trials on Hyper-CL™ lens

3
Subscribe